

Special Issue

Role of Extracellular Vesicles in Health and Diseases—Implications for Digital Health

Message from the Guest Editor

Extracellular vesicles (EVs) are small membrane-bound particles released by cells that play a pivotal role in intercellular communication. In health, EVs contribute to maintaining homeostasis by participating in processes such as tissue repair, immune responses, and blood coagulation. Conversely, in disease states, EVs can have detrimental roles. For instance, cancer cells exploit EVs to promote tumor progression and metastasis by altering the tumor microenvironment, enhancing angiogenesis, and suppressing immune surveillance. Similarly, in neurodegenerative diseases, EVs can propagate pathogenic proteins between cells, contributing to disease spread. Additionally, in cardiovascular diseases, EVs can influence plaque stability and thrombosis. Thus, understanding the dual roles of EVs in health and disease is crucial, as doing so opens the door to novel diagnostic and therapeutic strategies, leveraging their respective biomarker potentials and therapeutic cargo delivery capabilities.

In this Special Issue focusing on the future role of EVs in digital health and systems health, we welcome contributions that provide novel research findings related to this focus.

Guest Editor

Dr. Allan Stensballe

Department of Clinical Medicine, Aalborg University, 249 Selma Lagerlöfs Vej, 9260 Gistrup, Denmark

Deadline for manuscript submissions

closed (30 November 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/203522

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).